By Sahil Pandey
Nov 10 (Reuters) – Mirum Pharmaceuticals said on Tuesday its experimental treatment for hepatitis delta, a serious liver infection, led to reduced virus and normal liver enzyme levels, meeting the main goal of a second late-stage study.
• The company said 59% of patients receiving weekly doses of brelovitug achieved both outcomes after 24 weeks, compared with none in the delayed-treatment group
• The study enrolled 113 previously untreated patients, more than half of whom had cirrhosis, or advanced liver scarring
• Mirum said the latest study was the second of two supporting a planned US approval application for brelovitug, expected in the first half of 2027
• Citizens analyst Jonathan Wolleben said the results “meaningfully de-risk” brelovitug’s path to approval, as the second pivotal US study largely reproduced the efficacy and safety seen in the first
• Mirum reported in September that brelovitug met the same main goal in the first late-stage study
• Longer-term data showed all 15 cirrhosis patients treated for up to 108 weeks achieved reduced virus and normal liver enzyme levels, according to the company
• Mirum reported no new safety concerns, with flu-like illness being the most common side effect
(Reporting by Sahil Pandey in Bengaluru; Editing by Vijay Kishore and Jonathan Ananda)
Comments